Shots:

• In the P-I study- the companies will evaluate the OBDS with Ionis’ drug for in vitro compatibility and performance as well as in vivo safety- tolerability- and performance in a preclinical canine model
• Progenity expects that the alliance could demonstrate the versatility of OBDS in delivering a range of different molecules
• Ionis’ novel antisense therapies are designed to target mRNA- either decrease disease-causing proteins or increase the production of a needed protein while Progenity’s OBDS is an ingestible capsule based on a needle-free technology to enable the delivery of a drug formulated in a solution directly into the tissues of the small intestine

  Ref: GlobeNewswire | Image: BusinessWire